XML 12 R2.htm IDEA: XBRL DOCUMENT v3.24.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 6,518 $ 20,644
Short-term investments 5,124 0
Accounts receivable and other receivables, net of allowance for doubtful accounts of $0 and $3 as of December 31, 2023 and 2022, respectively 514 1,221
Inventories, net — current 1,958 2,321
Assets held for sale 51 87
Prepaid expenses and other current assets 807 795
Current assets of discontinued operations 0 330
Total current assets 14,972 25,398
Property and equipment, net 384 680
Right of use assets 792 1,848
Inventories, net — noncurrent 3,354 767
Intangible assets, net 39 40
Other noncurrent assets 164 165
Noncurrent assets of discontinued operations 0 24
Total assets 19,705 28,922
Current liabilities:    
Accounts payable and accrued expenses 2,410 2,855
Operating lease liability - current 852 1,010
Current liabilities of discontinued operations 0 26
Total current liabilities 3,590 4,209
Operating lease liability - noncurrent 155 1,007
Common stock warrant and option liabilities 1,257 806
Other noncurrent liabilities 2,000 2,000
Total liabilities 7,002 8,022
Commitments and contingencies (Note 16)
Stockholders’ equity:    
Common stock, $0.001 par value-150,000,000 shares authorized as of December 31, 2023 and December 31, 2022; 1,285,337 and 616,079 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively. 65 65
Additional paid-in capital 284,515 278,827
Accumulated other comprehensive income 101 0
Accumulated deficit (271,840) (257,859)
Total Arcadia Biosciences stockholders’ equity 12,841 21,033
Non-controlling interest (138) (133)
Total stockholders' equity 12,703 20,900
Total liabilities and stockholders’ equity 19,705 28,922
Related Party [Member]    
Current liabilities:    
Other current liabilities 58 48
Nonrelated Party [Member]    
Current liabilities:    
Other current liabilities $ 270 $ 270